50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
NASDAQ:DRRX

DURECT - DRRX Stock Forecast, Price & News

$0.56
-0.01 (-0.88%)
(As of 09/27/2022 12:32 PM ET)
Add
Compare
Today's Range
$0.56
$0.57
50-Day Range
$0.43
$0.91
52-Week Range
$0.36
$1.44
Volume
3,201 shs
Average Volume
254,526 shs
Market Capitalization
$127.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DURECT MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.42mentions of DURECT in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$79,015 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.15) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

929th out of 1,071 stocks

Pharmaceutical Preparations Industry

448th out of 531 stocks

DRRX stock logo

About DURECT (NASDAQ:DRRX) Stock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

Innocoll and DURECT Announce U.S. launch of POSIMIR®
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings
11/01/2021
Today
9/27/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRRX
Employees
79
Year Founded
N/A

Profitability

Net Income
$-36,260,000.00
Net Margins
-292.71%
Pretax Margin
-292.71%

Debt

Sales & Book Value

Annual Sales
$13.98 million
Book Value
$0.25 per share

Miscellaneous

Free Float
216,831,000
Market Cap
$127.55 million
Optionable
Optionable
Beta
1.21

Key Executives

  • Dr. James E. Brown D.V.M. (Age 65)
    Co-Founder, CEO, Pres & Director
    Comp: $859.68k
  • Ms. Judy R. Joice (Age 65)
    Sr. VP of Operations & Corp. Quality Assurance
    Comp: $436.99k
  • Dr. Norman L. Sussman M.D. (Age 69)
    Chief Medical Officer
    Comp: $570.32k
  • Mr. Timothy M. Papp
    Chief Financial Officer
  • Ms. Jian Li M.B.A. (Age 52)
    Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.
  • Dr. Andrew R. Miksztal Ph.D.
    VP of Pharmaceutical R&D and Principal Scientist
  • Mr. Steve Helmer J.D.
    VP & Chief Patent Counsel
  • Dr. WeiQi Lin
    Exec. VP of R&D and Principal Scientist
  • Dr. Su Il Yum Ph.D. (Age 83)
    Exec. Officer













DRRX Stock - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

How have DRRX shares performed in 2022?

DURECT's stock was trading at $0.9859 at the beginning of the year. Since then, DRRX stock has decreased by 42.7% and is now trading at $0.5650.
View the best growth stocks for 2022 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to the consensus estimate of $2.18 million. DURECT had a negative net margin of 292.71% and a negative trailing twelve-month return on equity of 76.42%. During the same period last year, the firm posted ($0.05) EPS.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.94%), CM Management LLC (1.65%), Renaissance Technologies LLC (1.47%), Beirne Wealth Consulting Services LLC (1.35%), Gagnon Securities LLC (0.65%) and State Street Corp (0.34%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $0.57.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $128.68 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36,260,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.